- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
ADHD drug Adzenys addresses unmet need for patients, says GlobalData
12 February 2016 • Author: Victoria White
The recent FDA approval of Neos Therapeutics’ Adzenys will provide patients who have problems swallowing pills with easy-to-administer drug options, according to an analyst with research and consulting firm GlobalData.
Adzenys, an orally disintegrating drug developed to treat attention deficit hyperactivity disorder (ADHD) which is intended for use in patients aged six years or older, uses the company’s proprietary Rapidly Disintegrating Ionic Masking (RDIM) technology.
Rachel Markwick, Ph.D., GlobalData’s Analyst covering Neurology and Ophthalmology, states that RDIM provides an extended release of amphetamine in the form of an orally disintegrating tablet, and includes taste-masking properties. As such, unmet needs within the ADHD market will be addressed for those who dislike swallowing tablets, or find it difficult, including both children and adults.
Markwick comments: “The technology used in Adzenys, which Neos plans to launch in Q2 of 2016 and make available in six dosage strengths, is also being utilized for another of the company’s late-stage ADHD candidate drugs, Cotempla XR-ODT (methylphenidate), which is likely to be launched in early 2018.
“GlobalData believes that while Adzenys and Cotempla will be helpful additions to the ADHD treatment space, Adzenys may initially encounter some skepticism, as Shire’s Vyvanse can already be sprinkled onto food.”
Adzenys uptake driven by its bioequivalence to Adderall XR
Despite this, the drug’s uptake will be driven by its demonstrated bioequivalence to Adderall XR, which is not common for reformulation products in ADHD that are typically compared to placebos.
Markwick continues: “Adzenys may be positioned early in the treatment paradigm as a comparable alternative to Adderall XR, one of the most highly prescribed drugs for ADHD in the US.
“By reformulating both amphetamine and methylphenidate, Neos will maximize its potential patient population. While the ultimate market share of both drugs may be limited by their niche roles in the ADHD arena, they offer clinical advantages that will help position Neos as an emerging player in a crowded treatment market.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics